Literature DB >> 15647406

Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma.

Kai Richter1, Frank Kanniess, Christian Biberger, Ruediger Nave, Helgo Magnussen.   

Abstract

Ciclesonide is a novel inhaled corticosteroid that is converted in the lungs to its active metabolite, desisobutyryl-ciclesonide (des-CIC). The aim of this study was to compare the deposition of ciclesonide, as well as its conversion to des-CIC, in the oropharyngeal cavity with fluticasone propionate (FP) following inhalation via hydrofluoroalkane-propelled metered-dose inhalers (HFA-MDIs). Eighteen asthmatics inhaled ciclesonide 800 microg followed by FP 1000 microg or vice versa in an open, randomized, 2-treatment, 2-sequence study design. The oropharynx was washed out immediately and at 15, 30, 45, and 60 minutes after inhalation. Samples were analyzed for ciclesonide, des-CIC, and FP using liquid chromatography with tandem mass-spectrometric detection. Concentration-time curves and area under the concentration-time curve (AUC) were calculated for each drug. Ciclesonide and FP were recovered in almost all samples. Within 60 minutes after inhalation, the amounts of both ciclesonide and FP decreased sharply, and low residual levels were detected after 30 minutes. des-CIC was detected in relatively low concentrations, with maximum concentration 30 minutes following inhalation. The AUC(0-60 min) for ciclesonide (250.4 nmol x h/L) and des-CIC (37.8 nmol x h/L) were found to be significantly lower compared with FP (636.2 nmol.h/L, P < .001). Approximately 50% less ciclesonide and 90% less metabolite were present in the oropharynx compared with FP. Less than 20% of the residual ciclesonide in the oropharynx was metabolized to des-CIC. These findings indicate that oropharyngeal deposition of ciclesonide is only half that of FP following inhalation from an HFA-MDI. Furthermore, there is little activation of ciclesonide to its active metabolite in the oropharynx, suggesting a decreased likelihood of inhaled ciclesonide-associated oropharyngeal side effects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647406     DOI: 10.1177/0091270004271094

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  21 in total

1.  The efficacy of immediate diet for reducing local adverse events of inhaled corticosteroid: a pilot study.

Authors:  Myoung Kyu Lee; Won Yeon Lee; Suk Joong Yong; Kye Chul Shin; Chong Whan Kim; Ji-Ho Lee; Saehyun Jung; Ye-Ryung Jung; Hyun Sik Kim; Tae-Sun Yu; Sang-Ha Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2012-08-31

2.  Successful treatment of eosinophilic esophagitis with ciclesonide.

Authors:  Shauna Schroeder; David M Fleischer; Joanne C Masterson; Erwin Gelfand; Glenn T Furuta; Dan Atkins
Journal:  J Allergy Clin Immunol       Date:  2012-04-03       Impact factor: 10.793

3.  Erratum to: Safety Considerations of Inhaled Corticosteroids in the Elderly.

Authors:  Salvatore Battaglia; Irene Cardillo; Federico Lavorini; Mario Spatafora; Nicola Scichilone
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

Review 4.  Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide.

Authors:  Rüdiger Nave
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 5.  Ciclesonide: a review of its use in the management of asthma.

Authors:  Emma D Deeks; Caroline M Perry
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Safety considerations of inhaled corticosteroids in the elderly.

Authors:  Salvatore Battaglia; Irene Cardillo; Federico Lavorini; Mario Spatafora; Nicola Scichilone
Journal:  Drugs Aging       Date:  2014-11       Impact factor: 3.923

Review 7.  Inhaled corticosteroids in children with asthma: pharmacologic determinants of safety and efficacy and other clinical considerations.

Authors:  Tanya Gulliver; Ronald Morton; Nemr Eid
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

8.  Inhalational Ciclesonide found beneficial in prevention of fat embolism syndrome and improvement of hypoxia in isolated skeletal trauma victims.

Authors:  R K Sen; S Prakash; S K Tripathy; A Agarwal; I M Sen
Journal:  Eur J Trauma Emerg Surg       Date:  2016-01-18       Impact factor: 3.693

Review 9.  Ciclesonide versus placebo for chronic asthma in adults and children.

Authors:  P Manning; P G Gibson; T J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

Review 10.  Ciclesonide versus other inhaled steroids for chronic asthma in children and adults.

Authors:  P Manning; P G Gibson; T J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.